AMSTERDAM – A combination of two Abbvie Inc. drugs, glecaprevir and pibrentasvir (G/P, previously ABT-493/ABT-530), helped 95 percent of noncirrhotic patients infected with the world's most common genotype of chronic hepatitis C virus (HCV) achieve undetectable levels of the virus in their blood at 12 weeks (SVR12), according to new data from the study, ENDURANCE-3, presented Saturday at the International Liver Congress.